Gina Columbus

Elizabeth Plimack, MD, discusses recent pivotal findings in the field of genitourinary malignancies, specifically renal cell carcinoma (RCC) and bladder cancer.

Emily M. Ko, MD, gives an overview of a study examining risk factors for surgical treatment delay for patients with endometrial cancer.

The c-MET inhibitor capmatinib (INC280) demonstrated early signals of efficacy with an overall response rate (ORR) of 20% when administered to patients with advanced c-MET–dysregulated non–small cell lung cancer (NSCLC).

The paradigm-changing findings of the phase III RESORCE trial will likely lead researchers to change how they treat patients with unresectable hepatocellular carcinoma (HCC) in the second-line setting, according to Richard Finn, MD.

In an interview with <em>Targeted Oncology</em>, Julio Pow-Sang, MD, chair of Urological Oncology at Moffitt Cancer Center, discussed the significance of assessing risk status, options for patients whose risk status falls in a &ldquo;grey-zone,&rdquo; and how technology is helping oncologists more accurately characterize risk.

The field of metastatic bladder cancer&mdash;an area that had long been stagnant&mdash;has quickly evolved with the recent FDA approval of atezolizumab (Tecentriq) coupled with the breakthrough therapy designation of nivolumab (Opdivo).

In an interview with&nbsp;<em>Targeted Oncology</em>,&nbsp;&nbsp;Richard Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center,&nbsp;&nbsp;discussed the selection of therapies available for patients with metastatic castration-resistant prostate cancer&nbsp;(mCRPC) and the next steps in the field.

Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy, according to prospective 5-year results of the MINDACT trial published in&nbsp;<em>The New England Journal of Medicine</em>.¹

Across the fields of renal cell carcinoma, bladder cancer, and prostate cancer, immunotherapy agents are moving through the pipeline and impacting patient outcomes&mdash;some quicker than others.

The treatment paradigm of metastatic urothelial carcinoma was shaken up in May 2016 when the FDA approved the PD-L1 inhibitor atezolizumab for the treatment of patients with locally advanced or metastatic disease.

For patients with prostate cancer, prostatectomy&mdash;whether laparoscopic or robotic&mdash;can provide a significant clinical benefit.

Over the past several years, the FDA approval of several novel agents has revolutionized the treatment of patients with metastatic castration-resistant prostate cancer.

Although immunotherapies, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), have generated great excitement in the field of squamous non-small cell lung cancer, a number of targeted agents are also gaining recognition.

While the United States Preventative Services Task Force has taken a stand against routine prostate-specific antigen screening for prostate cancer, updated findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial could flip opinions.

There have been limited successes made in immunotherapy in the treatment of patients with prostate cancer so far, but progress is being made, explains Akash Patnaik, MD, PhD, an assistant professor of Medicine at the University of Chicago Medicine.

Radium-223 dichloride has proved to be a game-changer in the radiopharmaceutical scene, specifically with the treatment of patients with metastatic castration-resistant prostate cancer.

Targeting the androgen receptor pathway in patients with castration-sensitive prostate cancer is a key component of treatment.

For patients with NRAS-mutant melanoma who progress following treatment with an immunotherapy agent, the MEK inhibitor binimetinib offers a promising option.

Screening for microsatellite instability in patients with colorectal cancer tumors is a significant step in determining which patients will benefit from immunotherapy, specifically pembrolizumab.

Current progress on targeted and immunotherapy agents for the treatment of sarcomas from the 2016 ASCO Annual Meeting were discussed with Jonathan C. Trent, MD, PhD.

Advancements in sarcoma are both revolutionizing the treatment of this heterogeneous disease and influencing the research and treatment approach in other tumor types, according to George D. Demetri, MD.

Michael E. Williams, MD, discusses emerging regimens on the horizon in mantle cell lymphoma, the potential of BCL-2 inhibition, and whether chemotherapy can be removed entirely from the treatment landscape.

The multikinase inhibitor lenvatinib (Lenvima) has quickly become the frontline standard of care for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), just one year following its initial approval, according to Renato Martins, MD.

Treatments can be better customized and tailored based on each patient's individual desires and characteristics, now that two effective options are available for refractory metastatic colorectal cancer, according to Jennifer Wu, MD.

Approximately 33% of patients with HER2-positive breast cancer have also been found to have a luminal subtype resistant to chemotherapy and trastuzumab. Peter Beitsch, MD, discusses the triplet neoadjuvant regimen of pertuzumab, trastuzumab, and chemotherapy, and its effect on the subtype in the Neoadjuvant Breast Registry Symphony Trial (NBRST) study.

The FDA has granted olaparib (Lynparza), a first-in-class oral PARP inhibitor, breakthrough therapy designation for patients with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC).

Despite the initial controversy caused over 6 years ago, the US Preventive Services Task Force (USPSTF) has released a final version of its guidelines that stick to its initial assessment.

A correlation was drawn between adjuvant hormone therapy (AHT) and a 37% reduction in the risk of death in women with epithelial ovarian cancer, according to results of a 24-year study.

In the last 5 years, the treatment paradigm for patients with hematologic malignancies has seen vast changes. These alterations continue their progress in the field with groundbreaking data and new ideas presented at the 2015 American Society of Hematology Annual Meeting from December 5 through 8.

Data showed patients with the HER2-enriched subtype had a high pCR with both single and dual anti-HER2 therapy and a high level of intertumoral heterogeneity.